Takeda Pharmaceutical (TAK) Return on Capital Employed (2019 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Return on Capital Employed of 3.34% for Q2 2026, down 265.0% year-over-year from 2.02% in Q2 2025, and little changed quarter-over-quarter from 3.34% in Q1 2026.
Takeda Pharmaceutical (TAK) Return on Capital Employed (2019 - 2026) Analysis & Trends
Takeda Pharmaceutical's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 3.34% for Q2 2026.
- In Q2 2026, Return on Capital Employed fell 265.0% year-over-year to 3.34%; the TTM figure through Jun 2026 stood at 3.34% (down 265.0% YoY), while the FY2026 annual figure was 0.05%, down 267.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 3.34%, roughly flat from 3.34% in the prior quarter.
- The five-year high for Return on Capital Employed was 7.1% in Q3 2023, with the low at 3.22% in Q4 2025.
- The 5-year median for Return on Capital Employed is 5.8% (2025), against an average of 5.6%.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed soared 206 bps in 2022, then tumbled 265 bps in 2026.
- Takeda Pharmaceutical's Return on Capital Employed stood at 6.02% in 2022, then gained by 16 bps to 6.99% in 2023, then retreated by 24 bps to 5.33% in 2024, then sank by 40 bps to 3.22% in 2025, then climbed by 4 bps to 3.34% in 2026.
- Business Quant data shows TAK's Return on Capital Employed at 3.34% in Q2 2026, 3.34% in Q1 2026, and 3.22% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 3.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34% |
| Mar 31, 2026 | 3.34% |
| Dec 31, 2025 | 3.22% |
| Sep 30, 2025 | 5.86% |
| Jun 30, 2025 | 5.98% |
| Mar 31, 2025 | 5.73% |
| Dec 31, 2024 | 5.33% |
| Sep 30, 2024 | 6.60% |
| Jun 30, 2024 | 6.40% |
| Mar 31, 2024 | 6.89% |
| Dec 31, 2023 | 6.99% |
| Sep 30, 2023 | 7.10% |
| Jun 30, 2023 | 4.86% |
| Mar 31, 2023 | 5.18% |
| Dec 31, 2022 | 6.02% |
| Sep 30, 2022 | 5.66% |
| Jun 30, 2022 | 5.53% |
| Mar 31, 2022 | 6.72% |
| Dec 31, 2021 | 5.78% |
| Sep 30, 2021 | 6.10% |